Sanofi, Regeneron lose bid to overturn Amgen win in patent case
A federal judge on Tuesday refused to throw out a court verdict upholding two Amgen Inc patents related to the company's cholesterol drug, a defeat for Sanofi SA and Regeneron Pharmaceuticals Inc, which make a rival drug. In an October 2014 lawsuit, Amgen had sought to stop Paris-based Sanofi and Tarrytown, New York-based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California-based company's patents related to the protein.
Continued here:
Sanofi, Regeneron lose bid to overturn Amgen win in patent case
About Author
Sanofi, Regeneron lose bid to overturn Amgen win in patent case
A federal judge on Tuesday refused to throw out a court verdict upholding two Amgen Inc patents related to the company's cholesterol drug, a defeat for Sanofi SA and Regeneron Pharmaceuticals Inc, which make a rival drug. In an October 2014 lawsuit, Amgen had sought to stop Paris-based Sanofi and Tarrytown, New York-based Regeneron from selling Praluent, a drug intended to lower bad LDL cholesterol by blocking a protein known as PCSK9. Amgen makes a rival drug called Repatha, and it said Praluent infringed the Thousand Oaks, California-based company's patents related to the protein.
Read more from the original source:
Sanofi, Regeneron lose bid to overturn Amgen win in patent case
About Author
